MedPath

IDIENCE CO., LTD.

IDIENCE CO., LTD. logo
🇰🇷South Korea
Ownership
Holding
Established
2019-01-01
Employees
11
Market Cap
-
Website
http://www.idience.com

Clinical Trials

4

Active:0
Completed:3

Trial Phases

1 Phases

Phase 1:4

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials

Phase 1
4 (100.0%)

Food Effect Study of IDX-1197 in Healthy Subjects

Phase 1
Completed
Conditions
Healthy Male
Interventions
Drug: IDX-1197(After a meal)
Drug: IDX-1197(fasting)
First Posted Date
2022-01-24
Last Posted Date
2022-08-09
Lead Sponsor
Idience Co., Ltd.
Target Recruit Count
37
Registration Number
NCT05202912
Locations
🇰🇷

Seoul National University Hospital, Seoul, Korea, Republic of

Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer

Phase 1
Recruiting
Conditions
Gastric Cancer
Interventions
Drug: IDX-1197+XELOX
Drug: IDX-1197+Irinotecan
First Posted Date
2021-01-27
Last Posted Date
2024-09-27
Lead Sponsor
Idience Co., Ltd.
Target Recruit Count
100
Registration Number
NCT04725994
Locations
🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Astera Cancer Care, East Brunswick, New Jersey, United States

🇰🇷

Dong-A University Hospital, Busan, Korea, Republic of

and more 11 locations

Basket Trial of IDX-1197, a PARP Inhibitor, in Patients With HRR Mutated Solid Tumors (VASTUS)

Phase 1
Completed
Conditions
Solid Tumors
Homologous Recombination Repair Gene Mutation
Homologous Recombination Deficiency
Interventions
First Posted Date
2019-11-22
Last Posted Date
2024-09-27
Lead Sponsor
Idience Co., Ltd.
Target Recruit Count
310
Registration Number
NCT04174716
Locations
🇰🇷

Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea, Republic of

🇰🇷

National Cancer Centre, Goyang, Gyeongggi-do, Korea, Republic of

🇰🇷

Ajou University Hospital, Suwon, Gyeonggi-do, Korea, Republic of

and more 16 locations

Study to Assess the Safety & Tolerability of NOV140101(IDX-1197) in Patients With Advanced Solid Tumors

Phase 1
Completed
Conditions
Advanced Solid Tumors
Interventions
Drug: NOV140101 (IDX-1197)
First Posted Date
2017-10-23
Last Posted Date
2022-02-03
Lead Sponsor
Idience Co., Ltd.
Target Recruit Count
32
Registration Number
NCT03317743
Locations
🇰🇷

Asan Medical Center, Seoul, Songpa-gu, Korea, Republic of

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.